This document summarizes a presentation on advances in treating chronic pain and addiction. It includes:
- Presenters from PRIUM, American Airlines, and the Treatment Research Institute
- Learning objectives around chronic pain, psychosocial issues, Medicaid requirements for the ASAM Criteria, and implementing the criteria
- Disclosures from presenters about relevant relationships
- Overview of topics like the bidirectional relationship between physical and mental health, impacts of adverse childhood experiences, and the influence of stigma on substance use treatment
- American Airlines' workers compensation program which saw a 40% reduction in claims and lower pharmacy costs and disability after redesigning their approach to focus on early intervention and additional resources for employees with chronic
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Dr. Rick Sponaugle: Chronic Pain And AddictionRobert Lee
Dr. Rick Sponaugle: on Chronic Pain And Addiction presented at the Independent Retired Football Players Summit at the South Point Resort & Casino in Las Vegas May 2009
Team Lift: Predicting Medication AdherenceNeil Ryan
Medication adherence is a growing public health concern in the US. It is the extent to which patients are taking medications as prescribed by their healthcare providers. Simply put, are patients eating their pills on time?
We looked at patient data from Medicare part D program released by Centers for Medicare & Medicaid services. We built a prediction model to ascertain whether a patient would be adherent based on a variety of social, economic and behavioral aspects.
The PPACA of 2010PPACA of 2010 brought many changes to the types o.docxsuzannewarch
The PPACA of 2010
PPACA of 2010 brought many changes to the types of provider organizations available. ACOs and PCMHs are two new organizations formed under PPACA. Using the readings this week, discuss the origin, structure, and purpose of the new organizations formed under PPACA.
Using South University Online Library (for example, CINAHL) or the Internet, search any three articles from the list below and evaluate the challenges and opportunities facing payers and providers as ACOs and PCMHs are implemented:
The patient-center medical home and managed care: Times have changed, some components have not (Baird, 2011).
Patient-centered medical homes: Will health care reform provide new options for rural communities and providers? (Bolin, Gamm, Vest, Edwardson, & Miller, 2011)
Accountable Care Organizations: The case for flexible partnerships between health plans and providers (Goldsmith, 2011).
Payment reform for primary care within the accountable care organization a critical issue for health system reform (Goroll & Schoenbaum, 2012).
Accountable care organizations, the patient-centered medical home, and health care reform: What does it all mean? (Longworth, 2011)
Implementing accountable care organizations: Ten potential mistakes and how to learn from them (Singer & Shortell, 2011).
Based on your research, summarize your findings on the selected topics and compile your observations in a 5- to 6-page Microsoft Word document.
Support your responses with examples.
Cite any sources in APA format.
References
:
Baird, M. A. (2011). The patient-center medical home and managed care: Times
have changed, some components have not.
The Journal of the American
Board of Family Medicine
,
24
(6), 630–632.
Bolin, J. N., Gamm, L., Vest, J. R., Edwardson, N., & Miller, T. R. (2011).
Patient-centered medical homes: Will health care reform provide new
options for rural communities and providers?
Family & Community
Health
,
34
(2), 93–101.
Goldsmith, J. (2011). Accountable Care Organizations: The case for flexible
partnerships between health plans and providers.
Health Affairs
,
30
(1), 32–40.
Goroll, A. H., & Schoenbaum, S. C. (2012). Payment reform for primary care
within the accountable care organization a critical issue for health system
reform. JAMA:
The Journal of the American Medical Association
,
308
(6), 577–578.
Longworth, D. L. (2011). Accountable care organizations, the patient-centered
medical home, and health care reform: What does it all mean?
Cleveland Clinic Journal of Medicine
,
78
(9), 571–582.
Singer, S., & Shortell, S. M. (2011). Implementing accountable care
organizations: Ten potential mistakes and how to learn from them. JAMA:
The Journal of the American Medical Association
,
306
(7), 758.
Assignment 2 Grading Criteria
Maximum Points
Discussed the impact of health care reform on patients and prov.
This is a presentation that I give to medical professionals educating them on the role and potential use of social work in the hospital setting. I presented this on May 22, 2009 to the Trauma Education & Research Committee.
Similar to Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend (20)
Kana Enomoto, Acting Administrator, Substance Abuse and Mental Health Services Administration, keynote presentation at the National Rx Drug Abuse & Heroin Summit March 29, 2016
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Rx16 tpp tues_330_1_gavin_2saddy_3gastfriend
1. Advances in Treating
Chronic Pain and Addiction
Presenters:
• Michael Gavin, MBA, President, PRIUM
• Jennifer Saddy, Director of Workers’ Compensation,
American Airlines
• David R. Gastfriend, MD, Scientific Advisor, Treatment
Research Institute
Third-Party Payer Track
Moderator: Michael C. Barnes, JD, Executive Director,
Center for Lawful Access and Abuse Deterrence, and
Member, Rx and Heroin Summit National Advisory Board
2. Disclosures
• Michael Gavin, MBA; Jennifer Saddy; and
Michael C. Barnes, JD, have disclosed no
relevant, real, or apparent personal or
professional financial relationships with
proprietary entities that produce healthcare
goods and services.
• David R. Gastfriend, MD – Future royalty:
American Society of Addiction Medicine
3. Disclosures
• All planners/managers hereby state that they or their
spouse/life partner do not have any financial
relationships or relationships to products or devices
with any commercial interest related to the content of
this activity of any amount during the past 12 months.
• The following planners/managers have the following to
disclose:
– John J. Dreyzehner, MD, MPH, FACOEM – Ownership
interest: Starfish Health (spouse)
– Robert DuPont – Employment: Bensinger, DuPont &
Associates-Prescription Drug Research Center
4. Learning Objectives
1. Outline mental and behavioral issues and their
influence on chronic pain.
2. Identify strategies to address psychosocial pain
issues when managing chronic pain and claims
involving chronic pain.
3. Explain the basis and impacts of the new federal
requirements for state Medicaid directors to
implement the ASAM Criteria.
4. Describe a tool for implementing the new ASAM
Criteria requirement.
6. Disclosure Statement
Michael Gavin, President of PRIUM, wishes to disclose that
PRIUM is a wholly owned subsidiary of Ameritox. Michael
will present this content in a fair and balanced manner.
7. Learning Objectives
1. Outline mental and behavioral issues and their
influence on chronic pain.
2. Identify strategies to address psychosocial pain
issues when managing chronic pain and claims
involving chronic pain.
3. Explain the basis and impacts of the new federal
requirements for state Medicaid directors to
implement the ASAM Criteria.
4. Describe a tool for implementing the new ASAM
Criteria requirement.
8. Comorbid AMI, SUD, CNCP
“ 9 million persons
in the United States
report long-term
medical use of
opioids.”
- CDC MMWR 2012
Each of the individual populations drives significant healthcare costs; the intersections of the
populations represent particularly complex patients that require innovative and focused management
9. A. Disease impacts mental health
• 30% of those living with a non-communicable disease
report a concurrent mental disorder.1
B. Mental Health impacts physical health
• Conversely, more than two-thirds of people with a
mental disorder have been shown to have at least one
other chronic NCD. 1
C. Psychosocial and Socioeconomic status modify
both effects
• An individual of lesser social and economic status is
more likely to suffer comorbid mental illness with a
non-communicable disease or disorder. 2
1. (Druss BG, Mental disorders and medical comorbidity.)
2. (Marnett K, Epidemiology of multimorbidity and
implications for health care, research, and medical
education: a cross-sectional study.)
9
Bidirectional Association
Physical health and mental health are intrinsically linked. Psychological factors are reciprocally
interactive in the initiation and expression of the pathology of chronic disease.
10. • Adverse Childhood Exposures
• The most prevalent of the 7 measured exposures was
substance abuse in the household at (~26%)
• Likelihood of childhood exposure:
• 25% chance to have been exposed to 1 category
• 6% chance to have been exposed to 4 or more categories
• Likelihood of illicit drug use:
• 11% with 1 exposure
• 28% with 4 or more exposures
10
Predicting Substance Abuse
The ACE study followed Kaiser patients from 1995-97. While chronic disease and risky health behaviors
are strongly predicted by ACEs, interventions focused on children are far from implementation.
11. A. Duration1
• 1-year disability risk is doubled by each of:
– Receiving more than 7 day supply of opioids within the first 6 weeks post injury.
– Receipt of 2 opioid prescriptions in 6 weeks post injury.
– Receipt of >150mg MED in 6 weeks post injury.
B. Mortality2,3
• Nationally, persons with anxiety/depression have a 60% higher mortality and die an
average of 8 years earlier than persons without these illnesses.
• Anxiety/depression attribute to 88,000 deaths each year.
• Prescription painkillers killed more than 16,000 in 2013 or 44 people/day.
C. Expenditures4,5
• Employees treated for depression (most commonly occurring) incurred annual per
capita health and disability costs of $5,415.
• Compared with claims not prescribed opioids, claims prescribed SA opioids are 2.8
times more expensive and claims prescribed LA opioids are 9.3 times more expensive.
1. GM Franklin et al., “early opioid prescription and subsequent disability among workers with back injuries: the Disability Risk Identification
Study Cohort.” Spine 33.2 (2008)
2. Pratt, Laura A., et al., “Excess mortality due to depression and anxiety in the United States.” General Hospital Psychiatry (2015)
3. CDC. National Vital Statistics System mortality data. (2015)
4. Druss, BG et al., “Health and disability costs of depressive illness in a major US corporation.” Am. Journal of Psychiatry 157.8 (2000)
5. White, JA., et al., “Thhe effect of opioid use on workers’ compensation claim cost in the state of Michigan. “J. of Occ and Env. Med (2012)
11
Impact on Claims
Comorbid AMI and CNCP are synergistically disabling and treated as a single disease state using
opiates. Co-occurring AMI and CNCP cause greater disability than each condition taken separately.
12. Primary Care Problem?
Family practice and internal medicine doctors are responsible for about 28 million opioid claims vs. a
little over 3 million for pain management and interventional pain management combined.
13. • Stigma contributes to a host of adverse
outcomes for people with SUD:
– Poor mental and physical health.1,2
– Non-completion of treatment for SUD.3
– Delayed recovery and reintegration.4,5
• Stigma also presents a barrier to treatment:
– Causing lowered utilization,6,7
– And differential treatment.8
Influence of Stigma
1. Stigma, discrimination and the health of illicit drug users. Ahern J., Stuber J., Galea S. Article Drug Alcohol Depend, 2007
2. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse
Link B., Struening E. L., Rahav M., Phelan J. C., Nuttbrock L. Article J Health Soc Behav, 1997
3. Perceptions of discriminatory treatment by staff as predictorsof drug treatment completion: utility of a mixed methods approach
Brener L., von Hippel W., von Hippel C., Resnick I., Treloar C. Article Drug Alcohol Rev, 2010
4. The contextual factors that foster and hinder the process of recoveryfor alcohol dependentwomen
Brewer M. K. Article J Addict Nurs, 2006
5. Nowhere to go: how stigma limits the options of female drug users after release from jail
van Olphen J., Eliason M. J., Freudenberg N., Barnes M. Article Subst Abuse Treat Prev Policy, 2009
6. Utilization of drug treatment programs by methamphetamine users: the role of social stigma
Semple S. J., Grant I., Patterson T. L. Article Am J Addict, 2005
7. Equity of access to treatment, and barriers to treatment for illicit drug use in Australia
Digiusto E., Treloar C. Article Addiction, 2007
8. Are drug treatment services only for ‘thieving junkie scumbags’? Drug users and the management of stigmatised identities
Radcliffe P., Stevens A. Article Soc Sci Med, 2008
14. Havassy BE, Alvidrez J, Mericle AA. Disparities in Use of Mental Health and
Substance Abuse Services by Persons with Co-occurring
Disorders.Psychiatric services (Washington, DC). 2009;60(2):217-223.
doi:10.1176/appi.ps.60.2.217.
14
Comorbid Treatment Rates
Patients with co-occurring disorders need to navigate two systems of care to obtain treatment. Those
who receive treatment in one sector may not receive adequate treatment in the other sector.
15. Political Hope?
“…we need a revolution in this country in
terms of mental health treatment.“
- Sen. Bernie Sanders
Democratic Presidential Debate, 1/17/16
"We have to move away from treating the
use of drugs as a crime and instead, move
it to where it belongs, as a health issue.”
- Sec. Hillary Clinton
Democratic Presidential Debate, 1/17/16
"You have the most conservative
Republican governors and the most
liberal Democratic governors agreeing"
on the urgent need to get something
done.
- Gov. Pete Shumliin, VT, NY Times, 2/22/16
“The victims of addiction deserve
treatment...“
- Gov. Chris Christie
ABC News, 1/12/16
“It’s very debilitating when you have a
loved one who’s struggling and you can’t
control it. I don’t know what it’s like to
lose a daughter. But I almost did.”
Gov. Jeb Bush
Huffington Post, 11/5/15
“This is a problem that, for me, I
understand firsthand.”
- Sen. Ted Cruz
Republican Presidential Debate, 2/6/16
17. THIRD-PARTY PAYER TRACK: ADVANCES
IN TREATING CHRONIC PAIN AND
ADDICTION
Jennifer Saddy, American Airlines
17
18. Learning Objectives
1. Outline mental and behavioral issues and their
influence on chronic pain.
2. Identify strategies to address psychosocial pain
issues when managing chronic pain and claims
involving chronic pain.
3. Explain the basis and impacts of the new federal
requirements for state Medicaid directors to
implement the ASAM Criteria.
4. Describe a tool for implementing the new ASAM
Criteria requirement.
19. • Redesign of the American Airlines Workers’
Compensation (WC) program in 2014 after
merger with US Airways
– Redefined the roles of the WC team
– Program covers over 120,000 employees and 3 wholly
owned subsidiaries.
– At least 15 union groups.
• New program focused on 2 claim tracks:
– New workers’ compensation claims,
– And the legacy on-going existing claims.
American Airlines WC
20. • Early intervention of the claim process and
additional resources provided for the employee
– Provide more meaningful interaction with the injured
employees
– Employer, Adjuster and Nurse Case Manager
• Direction of care & partner with the treating
physician (to the extent that is allowable per state
law).
• Collaboration and open communication between
all parties in the claims process
New WC Claims
21. • Early intervention is key to meaningful impact for
the injured employee
– Need to identify early red flags such as unclear
diagnosis and increasing opioid usage
• Provide the additional resources early in the
process to ensure appropriate treatment plan
– Treating physician
– Physician to physician discussions
– Nurse Case Manager
– Utilization Review
Chronic Pain Claims
22. • 5,874 WC claims open December 2013 some over
20 years old
• Goal was to resolve these claims but chronic pain
and pharmacy usage was a significant challenge
• Significant pharmacy usage in claims 2+ years old
and growing pharmacy trend and ongoing
disability
• Engaged pharmacy experts and physician
resources in attempts to change trajectory of
medical care to allow more function of the
injured employee
Existing WC Claims
23. • 40% reduction in open Workers Compensation
claims for American Airlines since December
2013
• Reduction in pharmacy costs by 5% (even with
30% more claims with the US Airways merger)
• Reduced disability by an average of 11 days or
25%
Results
24. Precise Data for Imprecise Behavior:
Why National Standards
Make a Difference
David R. Gastfriend MD
Chief Architect, CONTINUUMTM – The ASAM Criteria Decision Engine
Scientific Advisor – Treatment Research Institute
25. Disclosure of Relevant Financial Relationships
Name Commercial
Interests
Relevant
Financial
Relationships:
What Was
Received
Relevant
Financial
Relationships:
For What Role
No Relevant
Financial
Relationships
with Any
Commercial
Interests
David Gastfriend Recovery
Search
Alkermes
Kaleo
Indivior
Royalty from
ASAM, Inc.
Stock,Consulting
Consulting
Consulting
Pres. & CEO
Former VP, Sci.
Communications
Adv. Board
Adv. Board
26. ACA, Parity & Health IT Acts: Huge Implications
The Affordable Care Act (2010)
• Phasing-out fee-for-service
• Penalties now charged for preventable readmissions
• By 2018, 50% of CMS funds will be paid
through alternative payment methods
• Value-based payment, Case-based rates, Pay-for-performance
• Elevates importance of SUD because tens of millions
with higher SUD prevalence become insured
• SUD gets a seat at the table
…but will it be THE HOT SEAT???
27. ACA, Parity & Health IT Acts: Huge Implications
The Mental Health Parity and Addiction Equity Act (2008):
• Rules & lawsuits – slow in coming, but THEY’RE HERE
• Published medical necessity criteria, e.g., ASAM Criteria
• Equal coverage for SUD as for medical/surgical care
• No “non-quantitative treatment limits”
if not used for med/surg benefits (e.g., prior authorization)
• Kennedy Forum & TRI Online Appeals Guide
• SUD finally gets a seat at the table
www.thekennedyforum.org
www.tresearch.org
28. ACA, Parity & Health IT Acts: Huge Implications
The Health InfoTech (HITECH) Act (2009): Nowhere to hide
• Incentives for EHR adoption in general healthcare
• SUD behind the curve – competitive pressures now driving
• Data integration on the way…HIPAA & 42CFR – being resolved:
• SAMHSA’s Consent to Share (C2S) web-app is coming:
Patient selects which data can be shared
between which providers & systems
• Not only data storage/retrieval,
but also clinical decision support
and quality/outcomes tracking
…for pay-for-performance
29. PREVALENCE OF CO-MORBIDITY
(Medicaid; Percent with Chronic Medical +/- Behavioral Disease)
29
Hypertension
Diabetes
Coronary Heart
Disease
Congestive Heart
Failure
Asthma and/or
COPD
31.4%
32.1%
26.3%
30.1%
23.8%
68.6%
67.9%
73.7%
69.9%
76.2%
No Behavioral Health Problem With 1 or More Behavioral Health Problem
29
Boyd, C., Clark, R., Leff, B., Richards, T., Weiss, C., Wolff, J. (2011, August).
Clarifying Multimorbidity for Medicaid Programs to Improve Targeting and Delivering Clinical Services. Presented to SAMHSA, Rockville, MD.
30. IMPACT OF CO-MORBIDITY ON PER CAPITA COSTS
(Medicaid-Only Beneficaries with Co-Occurring Disorders)
30Boyd, C., Clark, R., Leff, B., Richards, T., Weiss, C., Wolff, J. (2011, August).
Clarifying Multimorbidity for Medicaid Programs to Improve Targeting and Delivering Clinical Services. Presented to SAMHSA, Rockville, MD.
30
31.
32. Addiction Assessment & Treatment Planning:
• Non-standard, “intuitive”, then “find out the rest later…”
• Managed Care wants more data: Telephone tag (90 min – 3 days)
• Most insurers’ medical necessity criteria are proprietary
• Absent precision & validity, emphasis is on cost, not quality
• 1991: ASAM Patient Placement Criteria…a teaching tool
• States create their own Criteria (CASAM, MASAM, NYSAM…)
• “ASAM” in Major US MCO: ~50% of cases were denials
• on appeal: ~50% reversed; on review ~50% reversed again!
• By 2000s, SAMHSA & CSAT called on ASAM for a standard
33. Modality Matching:
Many studies, e.g., Project MATCH – but few findings
(Gastfriend & McLellan, Med Clin NA, 1997)
Placement Matching:
Multiple studies; ASAM model – consistent signals
(Gastfriend, Addiction Treatment Matching, Haworth Press, 2004)
Support:
• NIDA: Validation - R01-DA08781 & K24-DA00427
• NIAAA: ASAM Software - SBIR grant R44-AA12004
• CSAT: Access to Recovery Initiative - grant 270-02-7120
• Belgian National Fund for Scientific Research
• Belgian American Educational Foundation
• Central Norway Health Trust /Rusbehandling Midt-Norge
• SAMHSA: Open Behavioral Health IT Architecture Program
Advances in Treatment Matching
34. ASAM Text: Hundreds of Decision Rules
To place patients in the least intensive & restrictive care
that meets the patient’s multi-dimensional needs
and affords optimal treatment outcome
www.ASAMcriteria.org
www.haworthpress.com
36. ASAM PLACEMENT CRITERIA
LEVELS OF 1. OUTPT 2. INTENSIVE 3. MED 4. MED
OF CARE OUTPT MON INPT MGD INPT
CRITERIA
Intoxication/
Withdrawal
no risk minimal some risk severe risk
Medical
Complications no risk manageable
medical
monitoring
required
24-hr acute
med. care
required
Psych/Behav
Complications no risk mild severity moderate
24-hr psych.
& addiction
Tx required
Readiness
For Change cooperative
cooperative
but requires
structure
high resist.,
needs 24-hr
motivating
Relapse
Potential
maintains
abstinence
more symptoms,
needs close
monitoring
unable to
control use in
outpt care
Recovery
Environment supportive
less support,
w/ structure
can cope
danger to
recovery,
logistical
incapacity
for outpt
37. • DSM-5 Substance Use Disorders: Diagnoses & Criteria
• CIWA-Ar & CINA withdrawal scores (alcohol/BZs, opioids)
• Addiction Severity Index (ASI) Composite Scores
• Imminent Risk Considerations
• Access & Support Needs/Capabilities
• ASAM Level of Care recommendations
– All adult admission levels and sub-levels
– Including Withdrawal Management
– Including Biomedically Enhanced Sub-level
– Including Co-occurring Disorder Sub-levels
(Capable, Enhanced)
• Also: If actual placement disagrees with Software,
the clinician gets to justify the discrepancy: Generating needs analysis data
Clinical Decision Support Software
38. Under-Matching Worsens No Show to Treatment
0%
10%
20%
30%
40%
50%
60%
70%
All Patients (N=700) Cocaine (N=183) Heroin (N=279)
From Inpatient Detox to Either Residential Rehab or Day Treatment:
All patients, High Frequency Cocaine Users and Heroin Users
Mis-matched Matched
p≤.001
p≤.001
p≤.019
Under-matched
patients’
no-show rate:
~25% worse
Under-matched
patients’
no-show rate:
~100% worse
Under-matched
patients’
no-show rate:
~300% worse
PercentNo-ShowstoNextTreatment
39. 3-mo Drop-Out, Improvement & Stepdown Need
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Under- Matched Over-
0
1
2
3
4
5
6
7
Under- Matched Over-
% of Patients Ready for
Stepdown at F/U (vs. BL)
# ASI Subscales
Improved at F/U% Drop Out at 3-Mo F/U
0%
10%
20%
30%
40%
50%
60%
70%
Under- Matched Over-
Stepdown
Same LOC
Higher LOC
Naturalistic Match Status – According to ASAM Software
40. 0
5
10
15
20
25
30
35
Adequate (II) Matched (III) Lesser LOC (IV)
~24-mos Before
~13 mos After
Bed-day Use Pre- vs. Post-Naturalistic L-III Placements
AnnualizedBed-Days
*
Bed-Day Utilization over 1-Yr in the VA
Bedford MA VA, N = 97
41. Conclusions
• ASAM Criteria: Parity-ready, published, medical necessity criteria
• The decision rules show face validity
• CONTINUUM™ technology provides good reliability & feasibility
• Good concurrent validity vs. other instruments
• Good Predictive validity overall, w/heroin, cocaine & comorbidity
• Studies show validity for undermatching, AND for overmatching
• Predictive validity found:
– across cultures/systems: public/VA; MA/NYC; Belgium/Norway
– at multiple time-frames: immediate, 30-d, 90-d & 1-year
– with multiple outcomes: no-show, global improvement,
substance use, step-down readiness, rehospitalization
42. Stakeholders in the Health IT Revolution
Client
Counselor
Supervisor
SystemManaged
Care
Employer/
Payer
Researcher
Accreditation Body,
Government
Society
43. • Operates 145 sites treating 30,000 people
• Largest behavioral health provider in U.S.
• Devotes significant resources to payer approval
• Each center has 3-5 FTEs dedicated to UR
• ~20% of cases are contested by payers
• ~30% of MD time is lost interacting w/payers
• If this administrative time is reduced only slightly,
the ASAM Software could yield substantial savings.
Case Study: CRC Health (now Acadia)
HARVARD | BUSINESS | SCHOOL
44.
45.
46.
47.
48.
49. ASAM’s CONTINUUM™:
(compared to usual assessment/placement)
• 25% - 300% reductions in no shows to next stage of treatment
• 30% reduction in dropout from treatment
• 3X improvement in addiction severity outcomes at 3 months
• 25% increase in numbers of patients ready for stepdown
Leading to…
• Increased patient flow & revenues
• Staffing efficiencies (fewer incomplete intakes & UR delays)
• Improved morale & bottom line
Addiction assessment:
A new, state-of-the-art standard
50. Survey of Addiction Providers with an EHR
83%
14%
3%
Have you asked your EHR technology vendor(s)
if they can provide CONTINUUM™ to you?
No, but I would like them
to have this capability
Yes
No, I am not interested
51. OPTIONS for States/Counties implementing the 1115 Waiver:
1. Managed care organization vendor contract – at a cost of millions
2. OR, ASAM’s CONTINUUM™ - at a fraction of the cost
July 27, 2015 SMD # 15-003
Re: New Service Delivery Opportunities
for Individuals with a Substance Use Disorder
Dear State Medicaid Director:
…States should use the ASAM Criteria as they develop a residential or inpatient SUD
service continuum…
In order to receive approval…the assessment for all SUD services, level of care
and length of stay recommendations must be performed by an independent third party
that has the necessary competencies to use ASAM Patient Placement Criteria.
Specifically, an entity other than the rendering provider will use the ASAM Criteria...
DEPARTMENT OF HEALTH & HUMAN
SERVICES Centers for Medicare & Medicaid
Services 7500 Security Boulevard, Mail Stop S2-
26-12 Baltimore, Maryland 21244-1850
52. A National Addictions Patient Registry
Client
Counselor
Supervisor
SystemManaged
Care
Employer/
Payer
Researcher
Accreditation Body,
Government
ASAM’s
National
Coalition
Treatment
Program
Protected
Raw Data
(Identifiers +
Health Info)
Copied Data
(Stripped of Identifiers
but with
Unique Case #)
EHR
53. Addiction assessment:
A new, state-of-the-art standard
THE PAST…
• Non-standard, intuitive
• Telephone tag
• Proprietary criteria
• Emphasis: cost, not quality
• 1991: ASAM…teaching tool
• State-by-state Criteria
• Managed Care Study:
~50% of denials reversed
• By 2000s, SAMHSA wants
a standard
NOW…
• Standardized, quantitative
• Rapid Prior Authorization
• Published criteria
• Emphasis on cost AND quality
• 2015: ASAM…a decision tool
• A national standard for Criteria
• Managed care: Willing to pilot
AUTOMATIC prior authorization
• 2015, SAMHSA
has a standard
54. Addiction assessment: A Sea Change
• Enough legislation already: Begin the quality change process!
• Consumers/Providers: Push for parity in managed care UR
e.g., via the Kennedy Forum/TRI Online Appeals Guide
• Payers/States/Accreditors: Measure program services,
e.g., TRI’s ASAM Level of Care Certification Program
• Payers/MCOs: Standardize medical necessity criteria/reform UR
– drop phone prior authorization
– manage by data: via ASAM’s CONTINUUM™ data registry
57. Advances in Treating
Chronic Pain and Addiction
Presenters:
• Michael Gavin, MBA, President, PRIUM
• Jennifer Saddy, Director of Workers’ Compensation,
American Airlines
• David R. Gastfriend, MD, Scientific Advisor, Treatment
Research Institute
Third-Party Payer Track
Moderator: Michael C. Barnes, JD, Executive Director,
Center for Lawful Access and Abuse Deterrence, and
Member, Rx and Heroin Summit National Advisory Board